NanoString Technologies Inc, Seattle, has expanded its 3D Biology portfolio with the commercial launch of the nCounter PanCancer Profiles, seven new gene expression panels designed to interrogate a focused area of cancer biology including immuno-oncology.
The panels are focused on adaptive immunity, cancer metabolism, intracellular signaling, cellular profiling, Wnt pathway, innate immunity, and DNA damage and repair. Each 192-gene panel includes 180 topic-specific probes and 12 universal housekeeping genes. Panels may be combined with nCounter protein expression modules to enable a deeper view of biology through simultaneous analysis of gene and protein expression in key areas of interest to cancer biologists, including immuno-oncology researchers.
“NanoString is excited to offer the power of 3D Biology technology in a series of focused PanCancer Profiles that enable our customers to measure gene and protein expression simultaneously,” says Joseph M. Beechem, PhD, senior vice president of research and development at NanoString Technologies. “We believe the power of 3D Biology technology will drive a new frontier of immuno-oncology biomarker discovery and utilization, enabling our customers to become leaders in developing a deeper understanding of the underlying biology and its relevance to cancer immunology.”
The new PanCancer Profiles leverage NanoString’s 3D Biology technology, enabling multiplexed digital assays that provide a deeper view of biology through the analysis of multiple analytes at once. Designed for flexibility, these panels can be used as assay development building blocks and may be combined with nCounter protein assays, creating new possibilities for researchers to interrogate both protein and RNA in a single experiment. By providing a menu of focused RNA profiling options, researchers can tailor their assay to meet the needs of their experiments. Panels may be customized with up to 24 additional gene expression targets defined by the user.
For more information, visit NanoString Technologies.
